Short report: evaluation of the potency and stability of a candidate vaccine against American cutaneous leishmaniasis.
Availability of a safe, immunogenic, and affordable vaccine would represent the best strategy for control of cutaneous leishmaniasis (CL). Stability in field conditions is a essential property for any candidate vaccine. The stability and immunogenicity of three different preparations (thimerosal-preserved, autoclaved, and lyophilized) of a killed Leishmania amazonensis vaccine were assessed using fresh products and after 12 months of storage at 4 degrees C. Autoclaving was associated with a time-dependent decrease in the immunogenicity of the vaccine, as measured by the leishmanin skin test and production of interferon-gamma. These findings are of importance in the decision of which preparation of candidate killed CL vaccines should move to phase III trials.
Mayrink
W
W
Departamento de Parasitologia, Instituto de Ciências Biológicas/Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Pinto
J
J
Da Costa
C
C
Toledo
V
V
Guimarães
T
T
Genaro
O
O
Vilela
L
L
D000328:Adult; D001938:Brazil; D004311:Double-Blind Method; D004355:Drug Stability; D004356:Drug Storage; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000302:isolation & purification; D016773:Leishmaniasis, Cutaneous / Q000517:prevention & control*; D008297:Male; D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated
D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated; D007371:Interferon-gamma